Jiangxi Institute of Biological Products Inc. (Jiangxi Bio) announced that the 30-day post-listing stabilization period for its Global Offering concluded on 25 July 2026 under section 9(2) of Hong Kong’s Securities and Futures (Price Stabilizing) Rules.

During the stabilization window, China International Capital Corporation Hong Kong Securities Limited, acting as Stabilizing Manager:

• Executed over-allocations totaling 5.44 million H shares in the International Offering, equal to 15.0 % of the initial offer size.

• Conducted market purchases of the same 5.44 million H shares at prices ranging from HK $7.40 to HK $10.46 per share (excluding standard fees and levies). The final repurchase was completed on 30 June 2026 at HK $9.78 per share.

The Overall Coordinators did not exercise the Over-allotment Option, which therefore lapsed on 25 July 2026. Consequently, no additional H shares will be issued.

Following these actions, Jiangxi Bio confirmed that its shareholding structure continues to meet the public-float requirement stipulated in Listing Rule 19A.13A(1).